Online inquiry

IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14472MR)

This product GTTS-WQ14472MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Dementia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14472MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2061MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ7617MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ13709MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ8370MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ7230MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ3265MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ13218MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ5132MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW